Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company was founded in 1969 and is based in Washington, the District of Columbia.
DHR Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for DHR, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Danaher Corp ranked in the 21th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for DHR, they are:
DHR's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 31.12% of tickers in our DCF set.
The weighted average cost of capital for the company is 8. This value is greater than merely 24.64% stocks in the Healthcare sector that generate free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Danaher Corp? See CPIX, AZN, RMD, BHC, and BIO.
Danaher Corporation (DHR): Q2 Non-GAAP EPS of $1.44 beats by $0.35; GAAP EPS of $1.24 beats by $0.50.Revenue of $5.3B (+19.4% Y/Y) beats by $290M.Core revenue growth of -0.5% vs. consensus of -5.0%.Press Release...